Sirona Biochem Corp V.SBM

Alternate Symbol(s): SRBCF

Healthcare Biotechnology

Sirona Biochem Corp. is a cosmetic ingredient and drug discovery company with a proprietary technology platform developed at its laboratory facility in France with a specialization in the stabilization of carbohydrate molecules. The Company is exploring the areas of diabetes, dyschromia, anti-aging, anti-cellulite and antiviral therapies and relies on a business model of licensing patents to large organizations in return for up-front and milestone payments as well as royalties. Its two most advanced programs are the cosmetic skin lightener and diabetes drug. The Company's TFC-1067 is for the treatment of Dyschromia (Dark spots on the skin). GlycoProteMim is a novel anti-aging compound. GlycoProteMim is based on the naturally occurring glycoproteins found in Antarctic fish, known to protect them against environmental stressors. It is focused on three current antiviral categories: Neuraminidase Inhibitors, Nucleoside Analogs and Iminosugars. Its wholly owned subsidiary is TFChem S.A.R.L.

TSXV:SBM - Post by User

Sirona Biochem Corp

Bullboard Posts

Post by stockarchangelon Oct 05, 2013 3:07pm

153 Views

Post# 21793915

This Is Ridiculous

From the Sirona website: "The market for recombinant proteins is expected to significantly rise with sales forecasted to reach $75.8 billion in 2012."

OK, we have the suspected new-fangled best entry (or at least competitive, very good entry) in 3 markets with combined sales over $200 billion. We have decent confirmation with LOIs with Cincinnati Childrens, Wanbang/Fosun, and Obagi/Valeant. Add to that the cancer antigen and the SGLT inhibitor. And we still have folks flipping for a half-penny. Go figure lol.

Bullboard Posts

Options trading in a volatile macro environment